Today, 8:08 AMSenseonics issues preliminary Q4 2025 revenue of approximately $14.2 million, expects 2025 revenue of $35.2 million, and introduces 2026 revenue guidance of $58–$62 million with projected 50% gross margin.
Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.